|
nasdaq:supn
|
503893
|
Apr 14th, 2024 12:00AM
|
Adamas Pharmaceuticals, Inc.
|
18K
|
47.00
|
Open
|
|
Apr 13th, 2024 10:30PM
|
Apr 14th, 2024 11:43AM
|
At Adamas, our mission and vision are clear: deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers, and society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.
|
Open
|
Parkinson's Disease, Multiple Sclerosis, and Alzheimer's Disease
|
Open
|
|
Emeryville
|
California
|
US
|
|
|
Supernus Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:supn
|
65514
|
Apr 14th, 2024 12:00AM
|
Supernus Pharmaceuticals, Inc.
|
16K
|
701.00
|
Open
|
|
Apr 13th, 2024 11:45PM
|
Apr 14th, 2024 11:43AM
|
We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our extensive expertise in product development has been built over the past 30 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, in late 2005, as Supernus Pharmaceuticals Inc. We market our products in the United States through our own specialty sales force and seek strategic collaborations with other pharmaceutical companies to license our products outside the United States.
We market Qelbree® (viloxazine extended-release) for the treatment of attention deficit/hyperactivity disorder (ADHD) in children ages 6 to 17. Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy, Apokyn® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD), Myobloc® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults, and Xadago® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility.
We are also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD in adults, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.
|
Open
|
CNS, Epilepsy, Migraine, Parkinson's Disease, Cervical Dystonia, and Chronic Sialorrhea
|
Open
|
9715 Key West Ave
|
Rockville
|
Maryland
|
US
|
20850
|
|
Supernus Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:supn
|
503893
|
Apr 13th, 2024 12:00AM
|
Adamas Pharmaceuticals, Inc.
|
18K
|
47.00
|
Open
|
|
Apr 12th, 2024 10:20PM
|
Apr 13th, 2024 12:10PM
|
At Adamas, our mission and vision are clear: deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers, and society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.
|
Open
|
Parkinson's Disease, Multiple Sclerosis, and Alzheimer's Disease
|
Open
|
|
Emeryville
|
California
|
US
|
|
|
Supernus Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:supn
|
65514
|
Apr 13th, 2024 12:00AM
|
Supernus Pharmaceuticals, Inc.
|
16K
|
701.00
|
Open
|
|
Apr 12th, 2024 11:37PM
|
Apr 13th, 2024 12:10PM
|
We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our extensive expertise in product development has been built over the past 30 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, in late 2005, as Supernus Pharmaceuticals Inc. We market our products in the United States through our own specialty sales force and seek strategic collaborations with other pharmaceutical companies to license our products outside the United States.
We market Qelbree® (viloxazine extended-release) for the treatment of attention deficit/hyperactivity disorder (ADHD) in children ages 6 to 17. Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy, Apokyn® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD), Myobloc® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults, and Xadago® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility.
We are also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD in adults, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.
|
Open
|
CNS, Epilepsy, Migraine, Parkinson's Disease, Cervical Dystonia, and Chronic Sialorrhea
|
Open
|
9715 Key West Ave
|
Rockville
|
Maryland
|
US
|
20850
|
|
Supernus Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:supn
|
503893
|
Apr 12th, 2024 12:00AM
|
Adamas Pharmaceuticals, Inc.
|
18K
|
47.00
|
Open
|
|
Apr 11th, 2024 10:24PM
|
Apr 12th, 2024 09:06AM
|
At Adamas, our mission and vision are clear: deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers, and society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.
|
Open
|
Parkinson's Disease, Multiple Sclerosis, and Alzheimer's Disease
|
Open
|
|
Emeryville
|
California
|
US
|
|
|
Supernus Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:supn
|
65514
|
Apr 12th, 2024 12:00AM
|
Supernus Pharmaceuticals, Inc.
|
16K
|
701.00
|
Open
|
|
Apr 11th, 2024 11:44PM
|
Apr 12th, 2024 09:06AM
|
We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our extensive expertise in product development has been built over the past 30 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, in late 2005, as Supernus Pharmaceuticals Inc. We market our products in the United States through our own specialty sales force and seek strategic collaborations with other pharmaceutical companies to license our products outside the United States.
We market Qelbree® (viloxazine extended-release) for the treatment of attention deficit/hyperactivity disorder (ADHD) in children ages 6 to 17. Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy, Apokyn® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD), Myobloc® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults, and Xadago® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility.
We are also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD in adults, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.
|
Open
|
CNS, Epilepsy, Migraine, Parkinson's Disease, Cervical Dystonia, and Chronic Sialorrhea
|
Open
|
9715 Key West Ave
|
Rockville
|
Maryland
|
US
|
20850
|
|
Supernus Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:supn
|
503893
|
Apr 11th, 2024 12:00AM
|
Adamas Pharmaceuticals, Inc.
|
18K
|
47.00
|
Open
|
|
Apr 10th, 2024 10:42PM
|
Apr 11th, 2024 11:51AM
|
At Adamas, our mission and vision are clear: deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers, and society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.
|
Open
|
Parkinson's Disease, Multiple Sclerosis, and Alzheimer's Disease
|
Open
|
|
Emeryville
|
California
|
US
|
|
|
Supernus Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:supn
|
65514
|
Apr 11th, 2024 12:00AM
|
Supernus Pharmaceuticals, Inc.
|
16K
|
701.00
|
Open
|
|
Apr 11th, 2024 12:27AM
|
Apr 11th, 2024 11:51AM
|
We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our extensive expertise in product development has been built over the past 30 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, in late 2005, as Supernus Pharmaceuticals Inc. We market our products in the United States through our own specialty sales force and seek strategic collaborations with other pharmaceutical companies to license our products outside the United States.
We market Qelbree® (viloxazine extended-release) for the treatment of attention deficit/hyperactivity disorder (ADHD) in children ages 6 to 17. Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy, Apokyn® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD), Myobloc® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults, and Xadago® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility.
We are also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD in adults, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.
|
Open
|
CNS, Epilepsy, Migraine, Parkinson's Disease, Cervical Dystonia, and Chronic Sialorrhea
|
Open
|
9715 Key West Ave
|
Rockville
|
Maryland
|
US
|
20850
|
|
Supernus Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:supn
|
503893
|
Apr 10th, 2024 12:00AM
|
Adamas Pharmaceuticals, Inc.
|
18K
|
47.00
|
Open
|
|
Apr 9th, 2024 10:28PM
|
Apr 10th, 2024 05:58PM
|
At Adamas, our mission and vision are clear: deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers, and society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.
|
Open
|
Parkinson's Disease, Multiple Sclerosis, and Alzheimer's Disease
|
Open
|
|
Emeryville
|
California
|
US
|
|
|
Supernus Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:supn
|
65514
|
Apr 10th, 2024 12:00AM
|
Supernus Pharmaceuticals, Inc.
|
15K
|
701.00
|
Open
|
|
Apr 9th, 2024 11:45PM
|
Apr 10th, 2024 05:58PM
|
We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our extensive expertise in product development has been built over the past 30 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, in late 2005, as Supernus Pharmaceuticals Inc. We market our products in the United States through our own specialty sales force and seek strategic collaborations with other pharmaceutical companies to license our products outside the United States.
We market Qelbree® (viloxazine extended-release) for the treatment of attention deficit/hyperactivity disorder (ADHD) in children ages 6 to 17. Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy, Apokyn® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD), Myobloc® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults, and Xadago® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility.
We are also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD in adults, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.
|
Open
|
CNS, Epilepsy, Migraine, Parkinson's Disease, Cervical Dystonia, and Chronic Sialorrhea
|
Open
|
9715 Key West Ave
|
Rockville
|
Maryland
|
US
|
20850
|
|
Supernus Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|